Background {#Sec1}
==========

Patients with chronic obstructive pulmonary disease (COPD) show a high number of comorbidities. One of the frequent comorbidities is diabetes mellitus, which is of particular relevance through its association with cardiovascular diseases. There is evidence that lung emphysema, a frequent phenotype in COPD, is initiated by changes of the alveolar-capillary system \[[@CR1]\]. On the other hand, diabetes is known to induce micro--- and macroangiopathy \[[@CR2]\], with microangiopathy causing nephropathy, retinopathy or neuropathy, and macroangiopathy contributing to the development of myocardial infarction, stroke and gangrene \[[@CR3]\]. Impaired capillary function may have a negative impact on alveolar gas exchange. This raises the question whether the vascular alterations associated with diabetes interact with those of COPD.

A clinically established measure of pulmonary capillary function is the diffusing capacity for carbon monoxide (CO) which is closely linked to the degree of lung emphysema as quantified by CT scans \[[@CR4]\]. On the other hand, patients with diabetes without known lung disease also may show a decreased CO diffusing capacity \[[@CR5], [@CR6]\], and impairment of pulmonary function in type I diabetes patients treated with insulin was linked to the quality of metabolic control \[[@CR7]\]. The combined effects of COPD and diabetes on the CO diffusing capacity are unclear. In patients with COPD and diabetes only studies on spirometry are available \[[@CR8]\], whereas the CO transfer factor has been measured only in diabetic patients without COPD. These considerations suggest a link between diabetes, emphysema and reduced diffusing capacity, but diabetes has also been associated with predominant airway obstruction \[[@CR9]\] which would imply a higher but not lower CO diffusing capacity relative to obstruction.

Based on the assumption that vascular alterations arising from diabetes could modify the reduction of CO diffusing capacity typically found in COPD, we analyzed the data of the *German* ***CO*** *PD and* ***Sy*** *stemic Consequences-* ***Co*** *morbidities* ***Net*** *work (COSYCONET).* This is a multi-center cohort study investigating the relationship of COPD with comorbidities. It includes 2741 patients of age ≥ 40 years with diagnosis of COPD, among them 376 patients with the reported comorbidity of diabetes. The hypothesis underlying our analysis was that the changes of CO diffusing capacity associated with diabetes and COPD add to each other reflecting the additional impairment of the capillary status due to diabetes. For this purpose we evaluated lung function, clinical and anthropometric data as well as biomarkers including HbA1c by multivariate regression analyses that took into account the factors influencing CO diffusing capacity, in terms of total lung transfer factor (TLCO) and volume-related transfer coefficient (KCO).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study analyzed data of the initial visit of the German COPD cohort COSYCONET. The cohort was recruited through the outpatient and inpatient sector, patients' organizations and media campaigns. Patients with previous lung transplantation, lung volume reduction surgery or lung malignancies were not eligible, as well as patients with moderate or severe exacerbations within four weeks prior to the visit. In the time period between September 2010 and December 2013 patients were examined in 31 study centers. The characteristics of the cohort have been described elsewhere \[[@CR10], [@CR11]\].

Assessments {#Sec4}
-----------

The patients' clinical and functional state was assessed by a wide spectrum of tests, with focus on pulmonary function and cardiovascular comorbidities. The assessments included a detailed history regarding concomitant diseases and regularly taken medication as well as the evaluation of biomarkers in blood and were guided by SOPs following established guidelines \[[@CR10]\]. Spirometric parameters comprised forced expiratory volume in one second (FEV~1~), forced vital capacity (FVC) and their ratio (FEV~1~/FVC); bodyplethysmographic parameters included intrathoracic gas volume (ITGV) and total lung capacity (TLC). The diffusing capacity for carbon monoxide (CO) was determined using the single-breath technique. This measurement yielded the transfer factor for CO (TLCO) and the transfer coefficient (KCO) as the ratio of TLCO and alveolar volume (VA). Predicted values for spirometry were taken from the Global Lung Function Initiative (GLI) data \[[@CR12]\], those for bodyplethysmography from Koch et al. \[[@CR13]\], except for ITGV \[[@CR14]\], and those for TLCO and KCO from van der Lee et al. \[[@CR15]\].

Diagnosis of COPD and diabetes {#Sec5}
------------------------------

The diagnosis of COPD was based on lung function impairment according to GOLD criteria \[[@CR16]\]. In addition to GOLD 1--4, patients of the former category GOLD 0 were included, i.e. patients with normal lung function according to the GOLD criteria but with symptoms of chronic bronchitis and a smoking history \[[@CR10]\]. Only patients with valid lung function data were included (*n* = 2,575) among whom 349 reported diabetes as diagnosed by a physician. Patients were grouped into four categories depending on the matching between the patients' report and either disease-specific or non-specific but disease-compatible medication: there were 268 patients with reported diabetes and diabetes-specific medication (A), 9 patients with diabetes-specific medication in the absence of a reported diagnosis (B). 24 patients took medication that was compatible with but not specific for diabetes (C), and 57 took no diabetes-related medication at all (D) \[[@CR17]\]. In the present analysis we defined diabetes by self-reported physician-based diagnosis irrespective of medication, or the intake of diabetes-specific medication in the absence of a reported diagnosis (*n* = 358; extended definition: A + B + C + D). For control purposes the results were compared with those obtained in patients defined by the presence of diabetes-specific medication only (*n* = 277; restrictive definition: A + B).

Statistical analysis {#Sec6}
--------------------

For data description mean values and standard deviations (SD) were used. The groups with and without diabetes were compared in a first step by unpaired *t*-test, categorical data were analyzed by the chi-square-test. As some variables showed deviations from normal distribution according to the Kolmogorov-Smirnov-test, we additionally used the Mann--Whitney-*U*-test as a non-parametric method to check the results. In a second step multivariate linear regression analyses were performed, or analysis of covariance (ANCOVA), with TLCO or KCO in %predicted taken as dependent measures and the binary categories diabetes and gender as independent factors, in addition to covariates. The following covariates were considered and eventually removed from the models in a stepwise backward elimination fashion: FEV~1~%pred, FEV~1~/FVC, sRaw (specific airway resistance), TLC%pred, BMI, packyears, hemoglobin (Hb) and HbA1c. The level of statistical significance was set at *p* = 0.05 and the statistical analyses were performed by SPSS Statistics 23 (IBM Corp., Armonk, NY, USA).

Results {#Sec7}
=======

Comparison of diabetes and non-diabetes group {#Sec8}
---------------------------------------------

Clinical and anthropometric characteristics are given in Table [1](#Tab1){ref-type="table"}, diabetes being defined either by the extended or the restrictive definition (see methods).Table 1Baseline characteristics of the subgroups with and without diabetesParameterNon-diabetes patientsDiabetes patients (extended def.)*p*-values (extended def.)Diabetes patients (restrictive def.)*p*-values (restrictive def.)Gender (m/f)1270/947(57/43%)262/96 (73/27%)*p* \< 0.001\*208/69 (76/24%)*p* \< 0.001\*Age (y)64.7 (±8.7)67.0 (±7.6)*p* \< 0.001\*67.1 (±7.5)*p* \< 0.001\*BMI (kg/m^2^)26.4 (±5.05)30.5 (±5.8)*p* \< 0.001\*30.69 (±5.1)*p* \< 0.001\*Waist circumf. (cm)97.7 (±15.1)110.0 (±14.7)*p* \< 0.001\*111.1 (±14.3)*p* \< 0.001\*Packyears46.8 (±34.8)55.3 (±40.9)*p* \< 0.001\*55.4 (±40.5)*p* \< 0.001\*Hb (mg/dl)14.66 (±1.38)14.43 (±1.39)*p* = 0.003\*14.46 (±1.32)*p* = 0.032\*HbA1c (%)5.76 (±0.47)6.91 (±1.0)*p* \< 0.001\*7.03(±1.13)*p* \< 0.001\*Creatinine (mg/dl)0.88 (±0.25)0.96 (±0.29)*p* \< 0.001\*0.95 (±0.27)*p* \< 0.001\*FEV~1~%pred59.7 (±22.2)59.8 (±21.2)*p* = 0.90659.6 (±20.0)*p* = 0.973FEV~1~/FVC54.8 (±13.6)55.3 (±13.2)*p* = 0.43154.5 (±13.0)*p* = 0.687FVC%pred78.6 (±19.1)79.1 (±19.1)*p* = 0.63878.0 (±18.7)*p* = 0.223TLC%pred112.9 (±30.4)107.2 (±27.6)*p* \< 0.001\*106.3(±27.3)*p* \< 0.001\*RV%pred150.1 (±47.2)143.4 (±45.2)*p* = 0.012\*142.4 (±43.5)*p* ≤ 0.011\*ITGV%pred146.6 (±36,8)135.1 (±36.0)*p* \< 0.001\*134.5 (±35.3)*p* \< 0.001\*TLCO%pred52.8 (±21.0)57.1 (±19.6)*p* \< 0.001\*57.0 (±19.2)*p* = 0.001\*KCO%pred66.1 (±23.8)75.6 (±23.4)*p* \< 0.001\*76.3 (±23.6)*p* \< 0.001\*GOLD 0/1/2/3/4269/242/868/679/159 (12/11/39/31/7%)68/33/133/103/21 (19/9/37/29/6%)*p* = 0.010\*51/26/107/78/15 (18/9/39/28/5%)*p* = 0.066GOLD A/B/C/D239/1198/32/735 (11/54/2/33%)37/170/12/138 (10/48/3/39%)*p* = 0.008\*32/130/10/104 (12/47/4/38%)*p* = 0.017\*The table shows mean values and standard deviations or absolute numbers, in case of gender and COPD classes additionally percentages (deviations of total from 100% are due to rounding). Column 3 shows the results of comparisons between the diabetes group (extended definition) and the complementary group of non-diabetes patients. Column 5 shows the corresponding results of comparisons between diabetes group (restrictive definition) and the corresponding group of non-diabetes patients. The comparisions between groups were performed by unpaired *t*-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in the case of categorical variablesSignificant (*p* \< 0.05) differences are marked with (\*)

When comparing the mean values between patients with and without diabetes, gender, age, BMI, waist circumference, packyears, hemoglobin, HbA1c, creatinine, TLC%pred, RV%pred, ITGV%pred, TLCO%pred, KCO%pred and the distribution of GOLD stages, both 1--4 and A-D, turned out to be significantly different (*p* ≤ 0.01 each). The results for the restrictive definition of diabetes were similar, but the distribution of GOLD stages 1--4 did not significantly differ, in contrast to GOLD A-D (*p* = 0.017). Moreover the non-parametric testing yielded the same distribution of significance across variables as the parametric testing.

In patients with diabetes, the prevalence of reported comorbidities was significantly higher for arterial hypertension, myocardial infarction, coronary heart disease, cardiac arrhythmia, dyslipidemia, peripheral neuropathy, gastrointestinal disorders, hyperuricemia (*p* \< 0.001 each) and osteoporosis (*p* = 0.047). The proportion of patients with asthma did not significantly differ between both groups.

Gender and diabetes {#Sec9}
-------------------

As the gender distribution differed between diabetic and non-diabetic patients, we stratified the parameters given in Table [1](#Tab1){ref-type="table"} according to gender; the results are given in Table [2](#Tab2){ref-type="table"}.Table 2Comparison of subgroups stratified according to diabetes and genderParameterMale patients(all)Male/non-diabetesMale/diabetes extended def.Female patients(all)Female/non-diabetesFemale/diabetes extended def.Age (y)65.8 ± 8.565.5 ± 8.667.1 ± 7.6°63.8 ± 8.7\*63.5 ± 8.7\*66.6 ± 7.4°BMI (kg/m^2^)27.4 ± 4.926.9 ± 4.630.1 ± 5.5°26.2 ± 5.8\*25.7 ± 5.5\*31.6 ± 6.5\*°Waist circumf. (cm)104.6 ± 13.6103.2 ± 13.0111.4 ± 14.2°91.6 ± 15.2\*90.2 ± 14. 4\*105.8 ± 15.4\*°Packyears54.0 ± 38.852.1 ± 38.057.2 ± 42.440.2 ± 28.7\*39.8 ± 28.6\*48.8 ± 34.7°Hb (mg/dl)15.02 ± 1.3815.09 ± 1.3814.66 ± 1.33°14.06 ± 1.16\*14.09 ± 1.13\*13.79 ± 1.36\*°HbA1c (%)5.98 ± 0.765.78 ± 0.486.94 ± 1.09°5.82 ± 0.64\*5.72 ± 0.45\*6.85 ± 1.15°Creatinine (mg/dl)0.97 ± 0.240.96 ± 0.231.00 ± 0.30°0.78 ± 0.23\*0.77 ± 0.23\*0.84 ± 0.21\*°FEV~1~%pred58.0 ± 21.758.0 ± 21.958.1 ± 20.362.2 ± 22.3\*61.9 ± 22.3\*64.6 ± 22.5\*FEV~1~/FVC54.5 ± 13.554.5 ± 13.554.8 ± 13.255.1 ± 13.755.0 ± 13.756.9 ± 13.2FVC%pred79.0 ± 18.879.0 ± 18.979.4 ± 18.778.0 ± 19.478.0 ± 19.378.3 ± 20.3TLC%pred100.0 ± 24.2100.0 ± 24.4100.0 ± 23.4129.9 ± 29.1\*130.1 ± 29.1\*127.6 ± 28.6\*RV%pred149.5 ± 48.1150.7 ± 48.8142.2 ± 42.0°144.4 ± 52.9149.5 ± 45.0144.0 ± 47.9ITGV%pred141.4 ± 36.2142.9 ± 36.2134.0 ± 34.9°150.3 ± 37.4\*151.5 ± 36.6\*138.0 ± 40.2°TLCO%pred55.2 ± 21.054.6 ± 21.458.0 ± 19.0°50.6 ± 20.4\*50.3 ± 20.2\*54.6 ± 21.1°KCO%pred70.6 ± 24.369.4 ± 24.577.1 ± 22.7°62.5 ± 22.6\*61.6 ± 22.2\*71.1 ± 25.0\*°GOLD 0/1/2/3/4166/159/597/484/126126/137/494/403/11040/22/103/81/16171/116/404/298/54\*143/105/374/276/49\*28/11/30/22/5\*°The table shows mean values and standard deviations or absolute numbers. Column 2 and 5 show the results of comparisons between females and males irrespective of diabetes, significant (*p* \< 0.05) differences are marked with (\*). Column 3 and 6 show the results of comparisons between females and males without diabetes, significant differences are marked with (\*). Column 4 and 7 show the results of comparisons between male and female diabetes patients, significant differences are marked with (\*). Column 3 and 4 shows the results of the comparison between male non-diabetes and male diabetes patients, significant (*p* \< 0.05) differences are marked with (°). Column 6 and 7 show the comparison between female non-diabetes and female diabetes patients, significant differences are marked with (°). The comparisons between groups were performed by unpaired t-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in the case of categorical variables

When comparing male and female patients irrespective of diabetes, most parameters were significantly different from each other (*p* \< 0.05), in particular those of CO diffusing capacity and FEV~1~%pred. The comparison within non-diabetic patients revealed a similar pattern of differences between males and females, including KCO%pred and FEV~1~%pred. Patients with diabetes showed a lower number of gender-related significant differences, including FEV~1~%pred but not TLCO%pred. The distribution of GOLD stages also differed between males and females, and this was true for the total group of patients (*p* \< 0.001), as well as non-diabetes (*p* \< 0.001) and diabetes patients (*p* = 0.030). With non-parametric testing the distribution of significances across variables remained the same except for KCO%pred in diabetes patients, which became non-significant.

Moreover Table [2](#Tab2){ref-type="table"} presents the results of comparisons between diabetic and non-diabetic patients for males and females separately. In males, age, BMI, waist circumference, hemoglobin, HbA1c and creatinine significantly differed between both groups, as well as RV%pred, ITGV%pred, TLCO%pred and KCO%pred (*p* \< 0.05 each). In females, age, BMI, waist circumference, packyears, hemoglobin, HbA1c and creatinine differed between the two groups, as well as ITGV%pred, KCO%pred and TLCO%pred (*p* \< 0.05 each). Non-parametric testing showed only for male patients a difference from parametric testing regarding creatinine which became non-significant.

Diffusing capacity versus functional/clinical parameters {#Sec10}
--------------------------------------------------------

For KCO%pred as dependent variable, multivariate linear regression analyses using as independent variables the parameters listed in Table [1](#Tab1){ref-type="table"} plus diabetes and backward selection, yielded gender, age, BMI, packyears, FEV~1~%pred, FEV~1~/FVC, TLC%pred, RV%pred, ITGV%pred (*p* ≤ 0.001 each) and creatinine (*p* = 0.033) as significant predictors (Table [3](#Tab3){ref-type="table"}). A similar analysis for TLCO%pred yielded gender, BMI, packyears, FEV~1~%pred, RV%pred, ITGV%pred and HbA1c (*p* ≤ 0.004 each) and creatinine (*p* = 0.035) (data not shown). In both analyses, diabetes was no significant predictor, neither as extended nor as restrictive definition. The relationship between KCO%pred, FEV~1~%pred and diabetes is illustrated in Fig. [1](#Fig1){ref-type="fig"} using adjusted values. It demonstrates the overlap between the two groups and the fact that there is no tendency towards lower values in diabetes patients after adjustment. When using the GOLD A-D categorization in addition to FEV~1~ and diabetes as predictors of KCO%pred, the GOLD categories turned out to be not significantly associated with KCO%pred. The same was true for TLCO%pred.Table 3Multivariate regression analysis with KCO%pred as dependent variableModellNon-standardized coefficientsStandardized coefficientsT*p*-valueRegression coefficient BStandard errorBetaConstant47.7076.3787.480.000Gender (m = 1.f = 2)−5.8101.160-.121−5.008.000Age (y).342.056.1236.150.000BMI (kg/m^2^)1.034.092.23711.256.000Packyears-.059.012-.091−4.894.000FEV~1~%pred.282.025.25711.140.000FEV~1~/FVC-.113.034-.066−3.346.001TLC%pred-.070.018-.089−3.883.000RV%pred.112.022.2215.127.000ITGV%pred-.253.028-.393−9.121.000Creatinine (mg/dl)−4.2531.991-.044−2.136.033 Fig. 1Relationship between KCO%pred and FEV~1~%pred. The regression lines refer to KCO%pred adjusted for FEV~1~%pred, TLC%pred, ITGV%pred, RV%pred, FEV~1~/FVC, packyears, age, gender, BMI, HbA1c (%) and creatinine. There was no significant difference between diabetic and non-diabetic patients (extended definition)

Lung function parameters {#Sec11}
------------------------

CO transfer factor and coefficient differed between diabetes and non-diabetes groups, if considered without adjustment for other variables (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The adjustment via multivariate regression analysis showed the difference in KCO%pred to be explained by a number of confounders, among them parameters of airway obstruction and lung hyperinflation. In order to reveal how much had to be attributed to these parameters, we repeated the regression analyses using only lung function parameters as independent variables. FEV~1~%pred, FEV~1~/FVC, TLC%pred, RV%pred, ITGV%pred, as well as gender and diabetes turned out to be significant predictors of KCO%pred (*p* ≤ 0.008 each). Analysis of covariance (ANCOVA) showed that there was no significant interaction term between gender and diabetes. In case of TLCO%pred, regression analysis revealed that FEV~1~%pred, RV%pred, ITGV%pred and gender were significant predictors (*p* \< 0.001 each) while diabetes was borderline non-significant (*p* = 0.056). When using the restrictive definition of diabetes, the results were qualitatively similar.

To reveal to which extent the other parameters were important in the adjustment of KCO%pred, we added each of these to lung function as predictors in the multivariate regression analysis. It turned out that BMI but not age, packyears or creatinine eliminated (*p* = 0.079) the significant difference between diabetes and non-diabetes that was seen with lung function parameters only. In a similar manner, for TLCO%pred the introduction of BMI eliminated (*p* = 0.918) the borderline effect of diabetes. Thus BMI appeared to be a decisive factor for the differences in CO diffusing capacity between diabetes and non-diabetes.

Discussion {#Sec12}
==========

The analysis of data from a large COPD cohort showed that there was no significant difference of CO transport parameters, especially TLCO%pred and KCO%pred, between patients with COPD and diabetes compared to non-diabetes COPD patients, provided that lung volumes, BMI and gender were taken into account as confounders. In particular, diabetes was associated with a reduction in lung volume and an increase in BMI. CO diffusing capacity was not deteriorated by the presence of diabetes. Instead, after adjustment for other parameters there was still a tendency towards better KCO values in diabetes. This finding differs from observations in diabetes patients without COPD who showed a slightly impaired CO diffusing capacity.

Our study population comprised all patients with complete lung function data and severity GOLD ≥0 from the COSYCONET cohort \[[@CR18]\]. This cohort is particularly suited for investigating the relationship between comorbidities and functional status \[[@CR10]\]. The information on medication allowed the definition of diabetes in terms of self-reported physician-based diagnosis and/or diabetes-specific medication; patients had been asked to bring all their medication to the study center \[[@CR10]\]. The extended definition was based on self-reported diagnosis and/or the presence of specific medication, the restrictive definition on the presence of diabetes-specific medication only and was used for sensitivity analyses \[[@CR17]\].

CO diffusing capacity is established in the evaluation COPD and lung emphysema \[[@CR5], [@CR19]\]. In diabetes patients with or without poor glycemic control or microangiopathic complications, but without lung disease, studies revealed a reduction of CO diffusing capacity and a restrictive pattern of spirometric parameters \[[@CR6], [@CR18], [@CR20]\], but no correlation with the duration of diabetes \[[@CR20]\]. The potential role of obesity was addressed by comparing diabetes with obese non-diabetes patients \[[@CR21]\]; TLCO was reduced in diabetes. In addition, diabetic neuropathy, macrovascular complications, impaired renal function and insulin treatment were linked to low TLCO \[[@CR21]\]. A meta-analysis summarized the association between diabetes and a restrictive lung function pattern in terms of FEV~1~, FVC and CO diffusing capacity, irrespective of BMI, smoking, diabetes duration and HbA1c levels in lung-healthy subjects \[[@CR22]\]. There are very few studies in patients with COPD and diabetes. Among diabetes patients with and without COPD only those from an "unclassified" sub-group according to standard GOLD categories showed a reduction of FEV~1~%pred and FVC%pred \[[@CR8]\]. Surprisingly, CO diffusing capacity has not been studied in patients with COPD and diabetes.

The presence of diabetes in COPD was associated with impairments of CO diffusing capacity beyond those attributable to COPD. On average, diabetes patients were older (Table [1](#Tab1){ref-type="table"}) and more often males compared to non-diabetes patients (75% in diabetes, 58% in the total cohort). Diabetic patients showed higher BMI, waist circumference, serum HbA1c and creatinine, and lower hemoglobin levels. They reported more packyears and cardiovascular comorbidities. The unadjusted mean values of lung function including CO diffusing capacity, differed between diabetic and non-diabetic patients. To account for the effect of gender, we stratified but many of the differences between diabetes and non-diabetes remained significant (Table [2](#Tab2){ref-type="table"}). Obviously, gender was not responsible for the differences between the two groups, particularly regarding KCO%pred.

To identify confounders we performed multivariate regression analyses. Both KCO (Table [3](#Tab3){ref-type="table"}) and TLCO depended on other lung function variables, laboratory parameters and gender, without significant effect of diabetes. We then reduced the set of predictors to lung function and gender, to reveal whether lung function was the major confounder. There was again a significant dependence on diabetes regarding KCO%pred but not TLCO%pred. Accounting for age, packyears or creatinine did not eliminate the difference of KCO%pred between non-diabetes and diabetes. When BMI and gender were chosen as predictors, the effect of diabetes became non-significant (*p* = 0.086); the use of BMI, lung function and gender as predictors completely abolished the effect of diabetes. Therefore, besides FEV~1~%pred, the major factor explaining the difference of KCO%pred between non-diabetes and diabetes appeared to be BMI. This is reflected in the large regression coefficients of BMI and FEV~1~%pred in Table [3](#Tab3){ref-type="table"}. Waist circumference did not yield as conclusive results as BMI; it was eliminated in most regression analyses, particularly in competition with BMI. To address the question whether the degree of glycemic control affected the result, we repeated the multivariate regression analyses using insulin-monotherapy (*n* = 65) or the presence of HbA1c values ≥8% (*n* = 46) as additional predictors. None of them emerged as significant regarding KCO and TLCO (data not shown). Patients of the restrictive definition showed higher levels of HbA1c and presumably had poorer glycemic control. However, the results regarding CO diffusing capacity essentially did not depend on the definition chosen.

These observations suggest that microangiopathic alterations caused by diabetes did not manifest as additional pulmonary vascular changes detectable through impaired CO diffusing capacity in COPD. The finding that the unadjusted transfer coefficient KCO was higher (by nearly 10%) in diabetes may be due to the reduction in lung volume and increase in BMI. Accordingly, the values of TLCO, a parameter which takes into account lung volume, were more similar, TLCO%pred being larger by only about 5% in diabetes. These findings suggest that in diabetes patients with COPD a reduction in lung volume and a higher BMI were responsible for the relatively increased values of unadjusted KCO%pred.

A recent radiological study reported diabetes as a risk factor for obstructive airway disease but not emphysema \[[@CR9]\]. This observation is in accordance with our findings insofar as reductions in CO diffusing capacity are more common in emphysema than obstructive airway disease per se. In view of the microvascular defects associated with diabetes \[[@CR23]\], it seems counterintuitive to link diabetes to airway obstruction rather than to an intrinsically vascular disease such as emphysema. From this point of view it seems remarkable that in our study the diabetes patients, at least on average, did not even show a tendency towards an impairment of CO diffusing capacity parameters, despite the fact that they reported a higher number of packyears and comorbidities, including cardiovascular diseases. This could be relevant as e.g. heart failure has a negative impact on CO diffusing capacity \[[@CR24]\]. It might well be that the changes in pulmonary capillary bed associated with lung emphysema are dominant over microvascular impairments associated with diabetes.

Noteworthy, systemic anti-inflammatory effects of anti-diabetic medication are increasingly considered \[[@CR25]\], such as metformin \[[@CR26], [@CR27]\], glucagon-like peptide-1 analogs \[[@CR28]\], sulfonylureas \[[@CR29]\], thiazolidinedione, DPP-4 inhibitors \[[@CR30]\] and insulin \[[@CR31]\]; all of them are inhibitors of NF-κB which plays a central role in COPD-associated inflammation \[[@CR32]\]. In non-diabetic patients metformin did not ameliorate acute exacerbations \[[@CR33]\], but exerted positive effects on symptoms, health status, inspiratory muscle function, lung hyperinflation and gas trapping in a prospective open-label study of moderate to severe COPD patients with diabetes and BMI \> 25 kg/m^2^ \[[@CR34]\]. Possibly the beneficial effects of anti-diabetic drugs on the lung occur only in the presence of definite inflammatory lung disease such as COPD.

In our study, most diabetes patients took medications of the type mentioned (*n* = 147 metformin monotherapy, *n* = 65 insulin monotherapy; *n* = 202 metformin combined with other oral specific medication, *n* = 31 plus insulin, *n* = 12 glinides, *n* = 23 DPP4I, *n* = 50 sulfonylureas, *n* = 7 incretin mimetics (non-exclusive groups)). Accordingly, it was not possible to define a sufficiently large control group of diabetes patients without such medication. Based on our data we cannot explain the reported impairment of CO diffusing capacity in non-COPD diabetes patients. Such a reduction might be derived from both a slight reduction of lung volume as an "external" factor and alterations of the pulmonary vascular bed as an "internal" factor reflecting morphological alterations in which inflammation plays a role. Both hyper- and hypoglycemic states have been reported to be associated with pro-inflammatory effect \[[@CR35], [@CR36]\] which theoretically could affect the lung. On the other hand it does not seem implausible in COPD patients the inflammatory part involved in the reduction of CO diffusing capacity is dominant over the diabetes part and more effectively targeted by the anti-inflammatory effects of the diabetes medication.

Limitations of the study {#Sec13}
------------------------

We could statistically adjust for a number of factors but mostly without interaction terms which would have required an even greater sample size. In addition the analysis was influenced by the unequal distribution of males and females across the two groups. This was relevant as even in the group without diabetes the parameters of CO diffusing capacity were gender-dependent. Information on the type and duration of diabetes was not available. The extended definition represented patients with lower HbA1c levels and probably better glycemic control compared to patients obeying the restrictive definition. A further grouping into patients with very poor glycemic control, e.g. HbA1c values ≥8% or insulin-monotherapy, did not yield conclusive results, probably due to the small sample sizes associated with these requirements. The statistical analyses indicated that the diabetes definition was not critical for the major finding, therefore the identification of diabetes patients was probably not a limiting factor in the study. A further limitation is that a detailed analysis of comorbidities was not possible due to the relatively small numbers that remained, particularly for their combinations, in the diabetes group. Moreover these comorbidities could not be verified by specific medication to the same extent as diabetes.

Conclusion {#Sec14}
==========

The analysis of data from a large COPD cohort showed that the transfer factor TLCO in terms of %predicted did not significantly differ between patients with and without diabetes, if other differences, especially those of lung function and body weight, were taken into account. The findings for the volume-related transfer coefficient KCO were similar but demonstrated the role of confounding factors such as lung volume and BMI with even greater clarity. Former investigations in diabetes patients without lung disease showed an impairment of CO diffusing capacity. Therefore, intuitively one might expect an additional reduction of diffusing capacity in COPD patients with diabetes and therefore be inclined to attribute a low value at least partially to diabetes. As a clinical implication, our study indicates that a reduction of diffusing capacity must be fully attributed to the lung disease and not to diabetes. This contrasts with other comorbidities, such as anemia which directly affects diffusing capacity. The question which factors may be responsible for our observations, remains open: either microvascular alterations caused by diabetes are not relevant in a lung disease such as COPD, or the common anti-diabetic drugs exert a beneficial, anti-inflammatory effect.
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